Assessment of Early Therapy Response with 18F-FLT PET in Glioblastoma Multiforme

ABSTRACTEarly therapy response assessment in glioblastoma multiforme remains a challenge. Evaluation by MRI relies on changes in tumor contrast enhancement or size, which are usually not visible at early therapy response assessment times. In addition, MRI may not be reliable for early therapy respon...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nuclear medicine 2014-10, Vol.39 (10), p.e431-e432
Main Authors: Oborski, Matthew J, Demirci, Emre, Laymon, Charles M, Lieberman, Frank S, Mountz, James M
Format: Article
Language:English
Subjects:
Brain Neoplasms - diagnostic imaging
Brain Neoplasms - surgery
Dideoxynucleosides
Female
Glioblastoma - diagnostic imaging
Glioblastoma - surgery
Humans
Middle Aged
Positron-Emission Tomography
Radiopharmaceuticals
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACTEarly therapy response assessment in glioblastoma multiforme remains a challenge. Evaluation by MRI relies on changes in tumor contrast enhancement or size, which are usually not visible at early therapy response assessment times. In addition, MRI may not be reliable for early therapy response assessment if only molecular changes have occurred. PET with F-FLT, a tracer associated with cellular proliferation, has been proposed as a potential method of early therapy response assessment and is an area of active research. We present a case where early response assessment with F-FLT PET was associated with a favorable 1-year follow-up outcome.
ISSN:0363-9762
1536-0229
DOI:10.1097/RLU.0000000000000321